在阿尔茨海默氏病中,与瞳孔相关的兴奋,皮质活动和认知
Michael C B David1,2, Emma-Jane Mallas1,2, Lucia M Li1,2
1UK Dementia Research Institute Care Research and Technology Centre, Imperial College London, London W12 0BZ, UK.
Brain communications
|July 23, 2025
概括
阿尔茨海默病会影响兴奋,影响注意力和认知. 综合瞳孔测量和EEG揭示了对刺激的异常兴奋反应,为治疗向提供了潜在的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 认知科学 认知科学
- 医疗成像医学成像
背景情况:
- 兴奋功能障碍与阿尔茨海默病 (AD) 有关,但人们对其了解甚少.
- 位置coeruleus是一个关键的核调节兴奋.
研究的目的:
- 使用瞳孔测量-EEG,研究阿尔茨海默病的强度和阶段性兴奋变化.
- 关联唤醒功能障碍与合体完整性和认知表现 (ADAS-Cog).
主要方法:
- 40名阿尔茨海默症患者和30名对照患者的同时瞳孔测量-EEG在休息期间和一个奇怪的任务.
- 核磁共振扫描 (MRI) 来评估部的完整性.
- 神经心理测试 (ADAS-Cog) 是一种神经心理测试.
主要成果:
- 阿尔茨海默病患者表现出较低的脑位完整性和较低的峰值α频率 (增强性兴奋),这两者都与ADAS-Cog得分有关.
- 阿尔茨海默病患者在奇怪的任务中表现出受损的行为表现,精度降低,反应时间较慢,更可变.
- 阶段性兴奋反应 (对突出刺激的瞳孔扩张) 在阿尔茨海默病患者的程度降低,并且较慢.
结论:
- 兴奋的波动在AD中是异常的,影响认知功能.
- 结合瞳孔测量-EEG可以测量AD的兴奋功能障碍.
- 这些措施可以作为生物标志物来识别患者的兴奋调节疗法.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
209
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
209
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262


